Drug Report History #246225
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-FR | Version v1-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated (Changed) | Updated to: 2025-03-13 | Was: 2024-12-20 |
| Drug Identification Number (Changed) | Updated to: 02248302 | Was: 02229048 |
| Brand name (Changed) | Updated to: MULTIHANCE | Was: ISOVUE 370 INJECTION |
| Common or Proper name | Gadobenate Dimeglumine injection | Gadobenate Dimeglumine injection |
| Company Name | BRACCO IMAGING CANADA | BRACCO IMAGING CANADA |
| Ingredients (Changed) | Updated to: GADOBENATE DIMEGLUMINE | Was: IOPAMIDOL |
| Strength(s) (Changed) | Updated to: 529MG | Was: 76% |
| Dosage form(s) (Changed) | Updated to: SOLUTION | Was: LIQUID |
| Route of administration (Changed) | Updated to: INTRAVENOUS INTRAVENOUS | Was: INTRAVASCULAR INTRAVASCULAR |
| Packaging size | 5ml, 10ml,15ml, 20ml, 50ml | 5ml, 10ml,15ml, 20ml, 50ml |
| Additional packaging sizes | ||
| ATC code (Changed) | Updated to: V08CA | Was: V08AB |
| ATC description (Changed) | Updated to: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA | Was: X-RAY CONTRAST MEDIA, IODINATED |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2024-12-17 | 2024-12-17 |
| Estimated end date (Changed) | Updated to: 2025-02-14 | Was: Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | The manufacturing and release of the product at the approved manufacturing site are suspended until issue is identified and resolved. | The manufacturing and release of the product at the approved manufacturing site are suspended until issue is identified and resolved. |
| Health Canada comments |